Bayerische Motoren Werke ADR (BMWYY)
29.20
+0.00 (0.00%)
OP · Last Trade: Oct 3rd, 9:49 AM EDT
Detailed Quote
| Previous Close | 29.20 |
|---|---|
| Open | - |
| Bid | - |
| Ask | - |
| Day's Range | N/A - N/A |
| 52 Week Range | N/A - N/A |
| Volume | 0 |
| Market Cap | - |
| PE Ratio (TTM) | - |
| EPS (TTM) | - |
| Dividend & Yield | N/A (N/A) |
| 1 Month Average Volume | - |
Chart
News & Press Releases
Tesla (NASDAQ: TSLA) has once again captured headlines with its robust third-quarter 2025 delivery performance, reporting record global vehicle deliveries that comfortably surpassed analyst estimates. This surge was primarily driven by an aggressive pull-forward of demand in the United States, as consumers rushed to capitalize on the expiring federal EV
Via MarketMinute · October 2, 2025
On October 2nd, 2025, electric vehicle giant Tesla (NASDAQ: TSLA) announced an unprecedented third quarter for vehicle deliveries, significantly surpassing even the most optimistic projections from Wall Street. This remarkable achievement immediately triggered a substantial rally in Tesla's stock, sending shares to new 2025 highs and pushing the company's market
Via MarketMinute · October 2, 2025
Rapid Spread of ‘Nightmare Bacteria’ Triggers Alarm
In 2013, former CDC director Tom Frieden observed that there were rising cases of ‘nightmare bacteria’, a category of bacteria characterized by three deadly attributes; resistance to all or almost all antibiotics, high mortality levels, and their ability to spread antibiotic resistance to other types of bacteria. From this triple threat of these microbes, one can understand why they are described as ‘nightmare bacteria.’ Data shows that cases of these bacteria are increasing at an alarming rate in the U.S.
Via Investor Brand Network · October 2, 2025
The nascent DePIN (Decentralized Physical Infrastructure Networks) sector has a new focal point in PEAQ ($PEAQ), a Layer 1 blockchain that burst onto the scene with its Token Generation Event (TGE) in September 2024. Following an initial public sale on CoinList in May 2024 and subsequent listings on major exchanges around November 2024, PEAQ witnessed [...]
Via BreakingCrypto · October 1, 2025
Oncotelic Therapeutics Inc. (OTLC) Venture Sapu Nano Receives Approval to Begin Human Clinical Trials of Sapu003, an Injectible Form of Afinitor(R) (Everolimus) for Breast Cancer Treatment
Sapu Nano, part of a group of companies formed through GMP Biotechnology Limited, which is a joint venture between Oncotelic Therapeutics (OTCQB: OTLC) and Dragon Overseas Capital Limited, recently received approval from the HREC in Australia to begin enrolling people in clinical trails of Sapu003 for the treatment of breast cancer.
Via Investor Brand Network · October 1, 2025
Lantern Pharma Inc.’s (NASDAQ: LTRN) AI-powered PredictBBB.ai Platform Helps Hoth Therapeutics Streamline Candidate Selection in Drug Development
Hoth Therapeutics (NASDAQ: HOTH), a biopharmaceutical company, recently announced that the company is using an AI-powered platform developed by Lantern Pharma (NASDAQ: LTRN), a clinical-stage biotech company and pharma, to streamline and improve the drug development process ( https://ibn.fm/VIL67 ).
Via Investor Brand Network · October 1, 2025
Scorpion Venom Shows Promise in Brain Tumor Treatment
The sight of a scorpion moving towards you with its stinger raised can send a chill down the spine of the bravest among us. If you watched Fear Factor, you saw how terrified the contestants were to come face to face with these creatures. While scorpions have been portrayed as the stuff of nightmares, scientists have found that they can be useful in the fight against brain cancer .
Via Investor Brand Network · September 30, 2025
On September 27, the World New Energy Vehicle Development Organization (WNEVDO) was officially established.
Via Get News · September 29, 2025
Soligenix Inc. (NASDAQ: SNGX) Advances Psoriasis Trial with Encouraging Patient Results, Market Potential
Psoriasis remains a persistent challenge for millions of patients worldwide, and promising new treatments are being closely watched by the medical and investor communities alike. Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company focused on rare diseases and inflammatory conditions, is advancing its treatment candidate, SGX302, in a phase 2a clinical trial for mild-to-moderate psoriasis. The company has already seen encouraging signals in earlier proof-of-concept work, and with its current study underway, Soligenix is positioning itself to expand its presence in dermatology with a novel therapeutic option for one of the most prevalent autoimmune skin conditions.
Via Investor Brand Network · September 29, 2025
Munich, Bavaria, Germany, September 29, 2025 -- On September 11-12, 2025, the 2nd Europe-China New Energy Vehicle Technology Conference was held in Munich, Germany. Dr. Richard Zhang, Managing Director of EVE Germany, attended and delivered a keynote speech titled "Rooted in Europe, Symbiosis and Growth." The speech outlined EVE Energy's business strategies in Europe and achievements in technological innovation, localized production, and sustainable development.
Via Press Release Distribution Service · September 29, 2025
Lucid's progress has been slow over the past several years. While production has gained some momentum recently, it's not enough to offset the company's losses.
Via The Motley Fool · September 28, 2025
In medical imaging, technology often races ahead of regulation. A recent proposal from the Centers for Medicare & Medicaid Services (CMS) underscores this tension: the agency is opting not to mandate radiation dose tracking for CT scans by 2027. While the decision reflects operational challenges hospitals face in meeting such requirements, it also highlights a growing consensus: patients, providers, and regulators all want sharper images with lower radiation exposure.
Via Investor Brand Network · September 26, 2025
Landmark Study Shows How Menopause Influences the Symptoms of Multiple Sclerosis
Groundbreaking research presented at the ECTRIMS 2025 conference held in Barcelona, Spain provides new insights into the ways in which menopause impacts the health implications and clinical manifestations in women who have multiple sclerosis. This study shows that changes in hormones influence the initial symptoms experienced by women with MS and also play a role in the comorbidities suffered by the affected individuals.
Via Investor Brand Network · September 26, 2025
German automaker BMW of North America LLC has issued a recall of over 196,355 units of its vehicles in the U.S. over a starter defect that can become a potential fire hazard.
Via Benzinga · September 26, 2025
September 25, 2025 – Tesla (NASDAQ: TSLA) shares experienced a notable decline today, trading lower amid broader market weakness and specific concerns stemming from a significant slump in its European sales performance. This downturn, which saw TSLA shares drop by over 3% to 4% throughout the day, trading around $424.54
Via MarketMinute · September 25, 2025
AmericanDreamAutoProtect Shares What Drivers Can Expect to Pay for Extended Car Warranties in 2025
When drivers think about extended car warranties, the first question that usually comes to mind is simple: How much does it cost?
Via AB Newswire · September 25, 2025
Feature Image: [Placeholder for an image of silver bars or a silver chart with an upward trend]
Delhi's bullion market witnessed a monumental event on Thursday, September 25, 2025, as silver prices surged to an unprecedented Rs 1.40 lakh per kilogram. This record-breaking rally, largely sustained since September 23,
Via MarketMinute · September 25, 2025
As of September 25, 2025, the financial markets are abuzz with anticipation surrounding silver, which appears to be on the verge of a monumental "historic breakout." Technical analysts are pointing to a rare and powerful 45-year "cup-and-handle" pattern on silver's long-term charts, a formation that, if confirmed, could unleash a
Via MarketMinute · September 25, 2025
Shares of automotive retailer Lithia Motors (NYSE:LAD)
fell 6.1% in the morning session after investor sentiment soured on the used-car retail sector as competitor CarMax reported weak second-quarter results that missed expectations.
Via StockStory · September 25, 2025
BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Appoints Mark Guerin as Chief Financial Officer
Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company developing therapies for neurodegenerative diseases, announced the appointment of Mark Guerin, CPA, CMA, CFM, as Chief Financial Officer to help guide the Company as its lead drug candidate, buntanetap, advances through late-stage trials. Guerin previously served as CFO of Onconova Therapeutics, now Traws Pharma (NASDAQ: TRAW), where he oversaw multiple financings and a merger that formed the new entity. His earlier roles include senior finance positions at Cardiokine, Barrier Therapeutics, and Coopers & Lybrand. Guerin said he is eager to support Annovis as it works to replicate buntanetap’s early success in registrational studies and deliver solutions for patients with Alzheimer’s and Parkinson’s disease.
Via Investor Brand Network · September 25, 2025
Researchers Find That Common Nutrient Could Supercharge the Immune Cells Fighting Cancer
A recently published study by a team at the University of Chicago suggests that a carotenoid called zeaxanthin, naturally occurring in plants like kale, spinach and orange peppers, and well known for its benefits in eye health, could also play a role in supercharging the immune system during the fight against cancer.
Via Investor Brand Network · September 25, 2025
As October approaches, all eyes in the financial world are fixated on Tesla (NASDAQ: TSLA), whose upcoming third-quarter 2025 earnings report is poised to be a pivotal moment for the electric vehicle (EV) giant. The report, expected around October 22nd, arrives at a critical juncture for the company, with market
Via MarketMinute · September 24, 2025
Soligenix Inc. (NASDAQ: SNGX) Strengthens Position in CTCL Treatment with HyBryte(TM) FLASH Results
Soligenix (NASDAQ: SNGX) is continuing to build momentum in its mission to advance HyBryte(TM), a first-in-class treatment for early-stage cutaneous T-cell lymphoma (“CTCL”). That progress is supported by results from its pivotal FLASH trial and its ongoing FLASH 2 confirmatory study. Together, the studies highlight not only the efficacy of synthetic hypericin activated by safe fluorescent light but also the company’s broader strategy to establish HyBryte as a new standard of care in a field where therapeutic innovation has lagged ( https://www.ibn.fm/G18Hp ). With statistically significant data already achieved and confirmatory enrollment well underway, Soligenix is taking important steps toward potential regulatory approvals Worldwide.
Via Investor Brand Network · September 24, 2025
HiLine Motors, a trusted name in luxury pre-owned vehicles across the Dallas–Fort Worth area, has officially opened the doors to its brand-new, state-of-the-art auto service and repair center . Conveniently located on its dealership lot at 4480 W Plano Parkway in Plano, Texas, the new facility is open to the public and welcomes all makes and models—luxury and non-luxury alike—including vehicles still under manufacturer warranty. This expansion adds a full suite of service options to HiLine's offerings, providing customers with one-stop access to high-quality auto sales, maintenance, and repair in one location.
Via Get News · September 24, 2025
BioMedNewsBreaks — Fifty 1 Labs, Inc. (OTC: FITY) Engages PCAOB Auditor to Support Planned OTCQB Uplist
Fifty 1 Labs (OTC: FITY), a Nevada-based holding company focused on AI-driven drug repurposing and functional medicine, announced it has signed a letter of engagement with a Public Company Accounting Oversight Board registered auditing firm to conduct audits of its 2024 and 2025 financial statements. The audits mark a key step in the company’s plan to uplist to the OTCQB Venture Market, which requires strict reporting and governance standards. CEO Paul Arora said the engagement underscores Fifty 1 Labs’ commitment to transparency and corporate governance, while laying the groundwork to strengthen investor confidence as it advances biotech and wellness initiatives.
Via Investor Brand Network · September 23, 2025